Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis

A therapeutic agent and a technology for use, applied in the fields of biochemistry, pathology, and molecular biology, can solve the problems of poor survival, high expression and poor effect of radiotherapy and chemotherapy, and short local recurrence-free intervals, etc.

Inactive Publication Date: 2015-06-03
INDIANA UNIV RES & TECH CORP
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

High expression of Ape1/Ref-1 is associated with poor effect of radiotherapy and chemotherapy, low complete response rate, short local recurrence-free interval, poor survival a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
  • Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
  • Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] The present invention relates to the application of anti-cancer and anti-angiogenesis agents that selectively inhibit the redox function of Ape1 / Ref-1. This selective inhibition includes specific inhibition, or, in other words, no or no appreciable effect on the BER function of Ape1 / Ref-1 and mainly affects redox function relative to BER function . The invention also encompasses the use of these agents in combination with other chemotherapeutic / therapeutic agents. Preferably said other agents act in a different manner to the patient than those agents which selectively inhibit the redox function of Ape1 / Ref-1.

[0038] Physiological diseases associated with altered angiogenesis encompass those diseases associated with inappropriate angiogenesis which is directly or indirectly detrimental to the patient. Altered angiogenesis promotion is associated with cancer (including growth, survival, migration, microenvironment and metastasis) as well as cardiovascular disease, chr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Apel/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Apel/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Apel/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Apel/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.

Description

[0001] This application is an invention patent application named "Benzoquinone derivative E3330 combined with chemotherapeutic agent for the treatment of cancer and angiogenesis" with the application number 200880117660.0 filed on September 22, 2008 and the priority date being November 21, 2007 divisional application. [0002] Cross References to Related Applications [0003] This application claims priority to U.S. Provisional Patent Application No. 60 / 989,566, filed November 21, 2007, and U.S. Provisional Patent Application No. 60 / 975,396, filed September 26, 2007, the entire contents of which are hereby incorporated by reference . technical field [0004] The present invention relates generally to the fields of molecular biology, biochemistry and pathology. More specifically, in some aspects, the present invention relates to the application of Ape1 / Ref-1 redox inhibitors in cancer treatment and angiogenesis inhibition. Background technique [0005] Apurinic / apyrimidini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61K45/06A61P35/00A61P35/02A61K33/243
CPCA61K31/201A61K31/7068A61K31/198A61K31/454A61K31/122A61K31/282A61K31/195A61K31/13A61K31/203A61K33/243A61K39/3955A61K45/06
Inventor 马克·R·凯利
Owner INDIANA UNIV RES & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap